Drug Trial Radar · NCT05014815
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
272
Actual
Start
Nov 16, 2021
Primary completion
Sep 4, 2024
Study completion Sep 4, 2024
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Aug 20, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that was locally advanced, could not be removed by surgery, or had spread to other parts of the body.
Conditions
- Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)
- Nonsmall Cell Lung Cancer, Stage IIIB
- Nonsmall Cell Lung Cancer, Stage IV
Interventions
OciperlimabDrug
900 mg intravenously (IV) once every 3 weeks (Q3W)
TislelizumabDrug
200 mg IV Q3W
CarboplatinDrug
Area under the concentration-time curve (AUC) of 5 or 6, administered on Day 1 of each 21-day cycle
PaclitaxelDrug
75 or 200 mg per square meter (mg/m²) of body surface area, administered on Day 1 of each 21-day cycle
Nab paclitaxelDrug
100 mg/m², administered intravenously on Days 1, 8, and 15 of each 21-day cycle
CisplatinDrug
75 mg/m², administered intravenously on Day 1 of each 21-day cycle
PemetrexedDrug
500 mg/m² administered intravenously on Day 1 of each 21-day cycle
PlaceboDrug
Administered intravenously Q3W to match ociperlimab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: From randomization up to the final efficacy analysis data cut-off date of 04 September 2024; Up to 33 months
Locations
64 sites in 8 countries. Site status is shown where the registry gives one.
Valkyrie Clinical Trials
Los Angeles, California
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Comprehensive Cancer Center of Nevada
Las Vegas, Nevada
Rj Zuckerberg Cancer Center
New Hyde Park, New York
North Shore Hematology Oncology Associates Dba New York Cancer and Blood Specialists (New York)
New York, New York
North Shore Hematology Oncology Associates Dba New York Cancer and Blood Specialists
Port Jefferson Station, New York
Ny Cancer and Blood Specialists
The Bronx, New York
Xcancerdayton Physician Network
Dayton, Ohio
Tennessee Cancer Specialist
Knoxville, Tennessee
Texas Oncology Tyler Longview
Austin, Texas
Cancer Care Northwest
Spokane Valley, Washington
Border Medical Oncology
East Albury, New South Wales, Australia
Northern Beaches Hospital
Frenchs Forest, New South Wales, Australia
Port Macquarie Base Hospital
Port Macquarie, New South Wales, Australia
Townsville University Hospital
Douglas, Queensland, Australia
Toowoomba Hospital
Toowoomba, Queensland, Australia
Launceston General Hospital
Launceston, Tasmania, Australia
Peninsula and South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia
Olivia Newton John Cancer Wellness and Research Centre
Heidelberg, Victoria, Australia
Klinik Penzing Wien, Abteilung Fur Atemwegs
Vienna, Austria
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Xinqiao Hospital Affiliated to the Army Medical University
Chongqing, Chongqing Municipality, China
Daping Hospital, Third Military Medical University
Chongqing, Chongqing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
Cancer Center of Guangzhou Medical University
Guangzhou, Guangdong, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Jingzhou Central Hospital
Jingzhou, Hubei, China
The First Peoples Hospital of Chenzhou
Chenzhou, Hunan, China
Changzhou Cancer Hospital
Changzhou, Jiangsu, China
Ansteel Group General Hospital
Anshan, Liaoning, China
Shandong Cancer Hospital
Jinan, Shandong, China
Liaocheng Peoples Hospital
Liaocheng, Shandong, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
The First Peoples Hospital of Kashgar
Kashgar, Xinjiang, China
Zhejiang Provincial Peoples Hospital
Hangzhou, Zhejiang, China
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.